Evidence map›Paper›PMID 25559813›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim, Nicole L Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Katherine L Pogue-GeileKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Nan SongKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Jong-Hyeon JeongKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Patrick G GavinKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Seong-Rim KimKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Nicole L BlackmonKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Melanie FinniganKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Priya RastogiKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Louis FehrenbacherKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Eleftherios P MamounasKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Sandra M SwainKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
D Lawrence WickerhamKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Charles E GeyerKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Joseph P CostantinoKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Norman WolmarkKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Soonmyung PaikKatherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. soon.paik@nsabp.org.
University of Pittsburgh · USKaiser Permanente · USAllegheny General Hospital · USYonsei University · KR

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
PRIMARY CANCER THERAPY GROUP--NSABP (HEADQUARTERS)U10CA012027 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2012
$117.2M
NSABP Foreign AccrualsU10CA037377 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2014
$116.5M
STUDY TO ASSESS RALOXIFENE FOR PREVENTING BREAST CANCERU10CA069974 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COSTANTINO, JOSEPH P. · 1995 to 2013
$62.4M
PRIMARY BREAST CANCER THERAPY--BIOSTATISTICS CENTERU10CA069651 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COSTANTINO, JOSEPH P. · 1995 to 2012
$52.1M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUG1CA233184 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ADAM M BRUFSKY, John Munn Kirkwood · 2019 to 2026
$7.7M
NCI NCTN-Network Lead Academic Site at UPCIU10CA180844 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRUFSKY, ADAM M, EDWARDS, ROBERT PAGE · 2014 to 2018
$4.5M
NCI NIH HHS U10 CA012027NCI NIH HHS U10 CA037377NCI NIH HHS U10 CA069651NCI NIH HHS U10 CA069974NCI NIH HHS U10-CA-12027NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180844NCI NIH HHS U10 CA180868NCI NIH HHS U10-CA-37377NCI NIH HHS U10-CA-69651NCI NIH HHS U10-CA-69974NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233184
6 · The paper itself

Abstract

purposeConsiderable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive value of these two biomarkers in the adjuvant setting using archived tumor blocks from National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. PATIENTS AND

methodsExpression data for 49 genes using the nCounter platform were used to generate PAM50 intrinsic subtypes for 1,578 archived tumor blocks from patients in the B-31 trial. Six PIK3CA hotspot mutations were examined by mass spectrometry of the primer extension products in a randomly selected subset (n = 671). We examined the heterogeneity of trastuzumab treatment effect across different subsets defined by each marker using Cox regression and disease-free survival as the end point.

resultsSeven hundred forty-one (47.0%) of 1,578 tumors were classified as HER2-enriched (HER2E) subtype, and 166 (24.7%) of 671 tumors had PIK3CA mutations. Hazard ratios (HRs) for trastuzumab in HER2E and other subtypes were 0.44 (95% CI, 0.34 to 0.58; P < .001) and 0.47 (95% CI, 0.35 to 0.62; P < .001), respectively (interaction P = .67). HRs for trastuzumab in PIK3CA wild-type and mutated tumors were 0.51 (95% CI, 0.37 to 0.71; P < .001) and 0.44 (95% CI, 0.24 to 0.82; P = .009), respectively (interaction P = .64).

conclusionUnlike results seen in the metastatic and neoadjuvant clinical trials, PIK3CA and PAM50 intrinsic subtypes were not predictive biomarkers for adjuvant trastuzumab in NSABP B-31. These data suggest that results from the metastatic and neoadjuvant setting may not be always applicable to the adjuvant setting.

Indexed as

MutationAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClass I Phosphatidylinositol 3-KinasesDisease-Free SurvivalDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingHumansNeoplasm StagingPhosphatidylinositol 3-KinasesPredictive Value of TestsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, humanTrastuzumab

Identifiers

PMID25559813
PMCPMC4397278
OpenAlexW2114149997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.